Non Hodgkin Lymphoma Clinical Trial
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who are refractory to, or intolerant of, all established therapy known to provide clinical benefit for their condition (i.e., trial subjects must not be candidates for any regimens known to provide clinical benefit). The study will consist of two parts: Part 1, dose escalation, and Part 2, dose expansion.
The study uses an accelerated dose titration design for dose escalation. Doses will be escalated using an N-of-1 per dosing cohort until the first instance of a treatment-related, clinically relevant Grade 2 non-hematologic toxicity or a Grade 3 hematologic toxicity of any type is observed during Cycle 1 (first 21 days). Following this a standard 3+3 trial design is used for all further escalation cohorts. Dose escalation is conducted independently for the two dose escalation tumor cohorts (MM and NHL). A recommended STRO-001 dose for expansion will be determined for MM and NHL.
The dose expansion (Part 2) portion of the study will begin when Part 1 is completed. Enrollment in dose expansion will include separate tumor cohorts of MM and NHL.
In both Part 1 and Part 2 of the study, STRO-001 will be dosed as an intravenous (IV) infusion on Day 1 of a 21-day cycle, until disease progression. Labs will be drawn on a weekly basis for Cycles 1-4, and every three weeks starting with Cycle 5. Weekly clinical evaluations will be conducted during the first 4 cycles; thereafter, clinical evaluations will be conducted on infusion days (Day 1 of each cycle). Samples for pharmacokinetics (PK) analysis will occur at specific times on Days 1, 2, and 8 of the first two cycles of treatment, Day 1 of the third cycle of treatment and at End of Treatment visit. Additional clinical evaluations and labs may occur at the discretion of the investigator.
Subjects who receive any dose of STRO-001 will be included in safety analyses. Disease evaluations will include peripheral blood analysis, bone marrow assessments and scans as appropriate. Disease status will be evaluated per MM-specific or NHL-specific criteria. Samples will be collected to assess the PK and immunogenicity of STRO-001. Biomarkers may be assessed from bone marrow, peripheral blood and/or tissue samples. Subjects will continue to receive study drug until disease progression, unacceptable toxicity, withdrawal of consent, or end of study (study completion).
Key Inclusion Criteria:
Confirmation of diagnosis
Relapsed or relapsed/refractory disease
Age ≥ 18 years
ECOG performance status (0-2)
Life expectancy > 3 months
Adequate bone marrow and renal functions
QTcF <500 msec
Ability to comply with treatment, PK and test schedules
NHL only- at least one measurable lesion
Key Exclusion Criteria:
Active plasma cell leukemia and/or leukemic manifestations of lymphoma
Known amyloidosis (MM patients)
Chronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects)
Sensory or motor neuropathy ≥ grade 2
Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Subjects may be using topical or inhaled corticosteroids.
Clinically significant cardiac disease
Significant concurrent, uncontrolled medical condition
History or clinical signs of meningeal or active CNS involvement
Known severe chronic obstructive pulmonary disease or asthma
History of significant cerebrovascular disease
Known Human Immunodeficiency Virus seropositivity
Positive serology for hepatitis B defined by a positive test for HBsAg
Concurrent participation in another therapeutic treatment trial
High screening liver function tests
Prior treatment with CD74 targeting therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 22 Locations for this study
Birmingham Alabama, 35294, United States
Tucson Arizona, 85711, United States
Duarte California, 91010, United States
Sacramento California, 95817, United States
San Francisco California, 94143, United States
Aurora Colorado, 80012, United States
Atlanta Georgia, 30322, United States
Indianapolis Indiana, 46202, United States
Fairway Kansas, 66205, United States
Baltimore Maryland, 21201, United States
Boston Massachusetts, 02114, United States
Detroit Michigan, 48202, United States
New York New York, 10029, United States
New York New York, 10065, United States
Eugene Oregon, 97401, United States
Austin Texas, 78705, United States
Dallas Texas, 75246, United States
Dallas Texas, 75390, United States
San Antonio Texas, 78229, United States
Fairfax Virginia, 22031, United States
Morgantown West Virginia, 26505, United States
Milwaukee Wisconsin, 53226, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.